From drug discovery to
IND Application
R&D acceleration
Cost reduction and efficiency improvement
From drug discovery to
IND Application
R&D acceleration
Cost reduction and efficiency improvement
Guangdong Guobiao Pharma-Tech Co., Ltd. is committed to becoming a globally leading innovative drug R&D company.We have built four core technology: ADC conjugation technology, long-acting drug product of peptides/small molecules, advanced complex drug product, and improved new drugs. We are dedicated to providing global clients with full lifecycle solutions—from drug discovery, pharmaceutical research, and registration, to industrial scale-up and commercialization.
The company owns a nearly 3,000 m² modern cGMP laboratory. Additionally, the company possesses deep expertise in high-end drug product such as complex injectables, suspensions, transdermal preparations, inhalation products, and solid dosage forms for poorly soluble drugs. The company is advancing multiple innovative pipelines, including a triple-target GLP-1 receptor agonist, with several improved new drug projects already in preclinical studies or at the Pre-IND stage
As a company honored as "Top 50 Pharmaceutical R&D Companies in 2023–2024," "Top 100 Innovative Enterprises of 'Science and Innovation Star' in 2024," "Top 20 of China CRO Excellence Brand List 2025," "Best Customer Satisfaction CRO Enterprise 2025," and "Top 50 Biotech Innovation in the Greater Bay Area," Guobiao Pharmaceutical adheres to the core values of "ultimate innovation and agile efficiency" and has independently laid out multiple innovative pipelines with "global first-in-class" potential.
Offering pharmacoeconomics-based market access guidance at the project planning stage to secure product advantages
covering R&D, pilot-scale production, and regulatory submission, to ensure high-quality CRO services
We provide clear guidance on regulatory requirements throughout the R&D process, ensuring all R&D services fully comply with official guidelines and CDE review standards
We maintain smooth communication channels during critical review phases to facilitate successful approval of submitted drug products
We operate in-house drug product platforms covering refined in vitro release testing and re-evaluation of Chinese Traditonal Medicine quality, catering to all stages from pharmaceutical R&D to application and marketing
During the product listing phase, our company will supported between experienced government affairs and market access experts,and offer good market regulatory resources
Precision Delivery and Solubilization of Poorly Soluble Drugs Platform
The platform focuses on poorly soluble active pharmaceutical ingredient (API) with narrow therapeutic windows, and relies on advanced delivery systems such as lipid microspheres/nanoemulsions and complex oral liquids.
2026101502987: An injection for delirium in critically ill ICU patients and postoperative cancer patients, preparation method and use thereof
2026105936947: An oral liquid preparation of aprepitant and preparation method thereof.
Long-Acting Delivery Platform for Peptides and Small Molecules
The platform is based on trinity technology of "prodrug modification - smart carrier - microsphere preparation", focusing on long-acting delivery of peptides and small molecules. Hydrophobic prodrugs are constructed through chemical modification to improve compatibility with PLGA carriers.
202610033029.2: A long-acting PLGA microsphere of lamivudine prodrug and its preparation method.
Thermo-Stable & Long-Acting Protein Delivery Platform
The platform addresses the poor thermal stability of protein drugs in aqueous solutions,overcomes the bottlenecks of mandatory cold-chain transportation and ultra-lowtemperature storage, and enables transportation and storage at ambient temperature.
CN 113248724 B: A solid protein drug preparation and preparation method thereof.
CN 113264997 B: A storage method for protein drugs at room temperature and high temperature.
CN 113248595 B: A long-term preservation method for protein.
CN 113248723 B: A preparation method of sustained-release preparation of protein drug.
pH-sensitive traceless reversible ADC conjugation technology platform
Relying on the internationally leading AzMMMan/DBCO copper-free click chemistry system, this platform provides an integrated ADC R&D technical service of "precision conjugation + efficient release + activity retention".
《Molecular Pharmaceutics》:Toward Artificial Immunotoxins: Traceless Reversible Conjugation of RNase A with Receptor Targeting and Endosomal Escape Domains.
《International Journal of Pharmaceutics》:Protein-drug conjugate programmed by pH-reversible linker for tumorhypoxia relief and enhanced cancer combination therapy.
Inhalation Drug Delivery Research Platform
Diverse dosage forms, precise particle size control, biomimetic model evaluation, prescription and device collaborative optimization, bioavailability enhancement technology, disease-oriented development, inhalation/spray characteristic in vitro evaluation.
Formoterol Fumarate Inhalation Solution
Revefenacin Inhalation Solution
Finasteride spray
Azelastine Hydrochloride Nasal Spray
Recently, Guobiao has assisted its partner, Jiangxi Yuanchao Pharmaceutical Technology Co., Ltd., in securing ...
More
June 3, 2026, Guangzhou — Today, Anhui Yongshengtang Pharmaceutical Co., Ltd. (hereinafter referred to as &quo...
More
On the morning of May 18, 2026, Guangzhou Daguang Pharmaceutical Co., Ltd. (hereinafter referred to as "D...
More
